Metabolic syndrome: Cardiovascular risk assessment and management

American Journal of Cardiovascular Drugs

Volumn 7, Issue 4, 2007, Pages 259-272

  Wong, Nathan D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; GLITAZONE DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; ROSIGLITAZONE;

ABDOMINAL OBESITY; ANKLE BRACHIAL INDEX; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIET THERAPY; DIETARY INTAKE; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMOBILIZATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; THROMBOSIS;

ADULT; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; METABOLIC SYNDROME X; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION;

EID: 34548075248     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707040-00004     Document Type: Review

References (76)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52
2. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005; 28: 2289-304
3. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-100
4. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745-9
5. Ko GT, Cockram CS, Chow CC, et al. High prevalence of metabolic syndrome in Hong Kong Chinese: comparison of three diagnostic criteria. Diab Res Clin Pract 2005; 69: 160-8
6. Tillin T, Forhouhi N, Johnston DG, et al. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study. Dibetologia 2005; 48: 649-56
7. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-76
8. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-50
9. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9
10. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9
11. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-78
12. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-14
13. Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003; 91: 1421-6
14. Third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143-3421
15. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34
16. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-4
17. Hunt KJ, Resendez RG, Williams K, et al., on behalf of the San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251-7
18. International Diabetes Federation. Worldwide definition of the metabolic syndrome [online]. Available from URL: http://www.idf.org/webdata/docs/IDF_Meta- syndrome_definition.pdf. [Accessed 2005 Aug 24]
19. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healothy American women. Circulation 2003; 107: 391-7
20. Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-5
21. Malik S, Wong ND, Frankin SS, et al. Cardiovascular disease in US persons with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-3
22. Vu JD, Vu JB, Pio JR, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus and pre-existing cardiovascular disease. Am J Cardiol 2005; 96: 655-8
23. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-25
24. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511
25. O'Leary DH, Polak JF, Kronmal RA, et al., for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22
26. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6
27. Criqui MH, Langer RD, Fronek A, et al. Coronary disease and stroke in patients with large vessel peripheral arterial disease. Drugs 1991; 42 Suppl. 5: 16-21
28. Wong ND, Hsu JC, Detrano RC, et al. Coronary artery calcium evaluation by electron beam computed tomography: relation to new cardiovascular events. Am J Cardiol 2000; 86: 495-8
29. Arad Y, Spadaro LA, Goodman K, et al. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000; 36: 1253-60
30. Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5,635 initially asymptomatic low to intermediate-risk adults. Circulation 2003; 107: 2571-6
31. Shaw LJ, Raggi P, Schisterman E, et al. Prognostic value of cardiac risk factors and coronary artery calcium for all-cause mortality. Radiology 2003; 228: 826-33
32. O'Malley PG, Taylor AJ, Jackson JL, et al. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asyptomatic populations. Am J Cardiol 2000; 85: 945-8
33. Wilson PWF, Smith SC, Blumenthal RS, et al. Task Force #4: how do we select patients for atherosclerosis imaging? 34th Bethesda Conference. J Am Coll Cardiol 2003; 41: 1898-906
34. Wong ND, Sciammarella MG, Polk D, et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol 2003; 41: 1547-53
35. Ellison RC, Zhang Y, Wagenknect LE, et al. Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta. Am J Cardiol 2005; 95: 1180-6
36. Kullo IJ, Cassidy AE, Peyser PA, et al. Association between metabolic syndrome and subclinical coronary atherosclerosis in asymptomatic adults. Am J Cardiol 2004; 94: 1554-8
37. Wong ND, Rozanski AR, Gransar H, et al. Metabolic syndrome increases the likelihood of inducible myocardial ischemia among patients with subclinical atherosclerosis. Diabetes Care 2005; 28: 1445-50
38. Ahluwalia N, Drouet L, Ruidavets JB, et al. Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis 2006; 186: 345-53
39. Burchfiel CM, Skelton TN, Andrew ME. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2005; 112: 819-27
40. McNeill AM, Rosamond WD, Girman CJ, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (the ARIC Study). Am J Cardiol 2004; 94: 1249-54
41. Tzou WS, Douglas PS, Srinivasan SR. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol 2005; 46: 457-63
42. Stone NJ, Saxon D. Approach to treatment of the patient with metabolic syndrome: lifestyle therapy. Am J Cardiol 2005; 96: 15E-21E
43. Samaha FF, Iqbal N, Seshadri P, et al. A low carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003; 348: 2074-81
44. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003; 348: 2082-90
45. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
46. Tuomilehto J, Lindstrom J, Eriksson JG, et al., for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among ausjbects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50
47. Austin MA, Rodriguez BL, McKnight B, et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000; 86: 412-6
48. Krauss R. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81: B13-7
49. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159: 2661-7
50. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9
51. Sever PS, Dahlof B, Poulter NR, et al., on behalf of the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-58
52. Colhoun HM, Betterridge DJ, Durrington PM, et al., CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-conrolled trial. Lancet 2004; 364: 685-96
53. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary or other atherosclerotic vascular disease: 2006 update. Circulation 2006; 113: 2363-72
54. Deedwania PS, Hunninghake DB, Bays H. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. Am J Cardiol 2004; 93: 18c-26c
55. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma-insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-604
56. Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005; 95: 254-7
57. Keech A, Simes RJ, Barter P, et al., for the FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): Randomised controlled trial. Lancet 2005; 366: 1849-61
58. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7
59. Volkova N, Deedwania PC. Dyslipidemia in the metabolic syndrome. In: Krentz AJ, Wong ND, editors. Metabolic syndrome and cardiovascular disease. New York: Informa Healthcare, 2007
60. Franklin SS. Hypertension in the metabolic syndrome. In: Krentz AJ, Wong ND, editors. Metabolic syndrome and cardiovascular disease. New York: Informa Healthcare, 2007
61. Franklin SS, Barboza M, Pio J, et al. Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. J Hypertension 2006; 24: 2009-16
62. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
63. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial pressure. J Hypertens 2003; 21: 1011-53
64. Appel LJ, Moore TJ, Obarzanek E, et al. The effect of dietary patterns on blood pressure: results from the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. N Engl J Med 1997; 336: 1117-24
65. Davis BR, Black HR. Clinical outcomes in participants with cardiovascular dysmetabolic syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [abstract]. Circulation 2004; 110: III-796
66. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihyprtensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Atack Trial (ALLHAT). Arch Intern Med 2005; 165: 1401-9
67. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with suphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
68. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformain on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
69. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trails/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53
70. The Diabetes Control and Compliations Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14): 977-86
71. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglatAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89
72. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368: 1096-105
73. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391-7
74. Malik S, Wong ND, Franklin SS, et al. Cardiovascular disease in U.S. persons with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-3
75. Pearson TA, Mensah GA, Alexander RW, et al. AHA/CDC scientific statement: marks of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Conrol and Prevention and the American Heart Association. Circulation 2003; 107: 499-501
76. Van Dielen FM, Buurman WA, Hadfoune M, et al. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 2004; 89: 4062-8